Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands.
Cell metabolism (Impact Factor: 16.75). 11/2011; 14(5):612-22. DOI: 10.1016/j.cmet.2011.10.002
Source: PubMed

ABSTRACT Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. Resveratrol significantly reduced sleeping and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid levels and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased. In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In vitro and animal studies have shown positive effects of resveratrol on lipid and lipoprotein metabolism, but human studies specifically designed to examine these effects are lacking. The primary outcome parameter of this study in overweight and slightly obese subjects was the effect of resveratrol on apoA-I concentrations. Secondary outcome parameters were effects on other markers of lipid and lipoprotein metabolism, glucose metabolism, and markers for inflammation and endothelial function. This randomized, placebo-controlled crossover study was conducted in 45 overweight and slightly obese men (n = 25) and women (n = 20) with a mean age of 61 ± 7 years. Subjects received in random order resveratrol (150 mg per day) or placebo capsules for 4 weeks, separated by a 4-week wash-out period. Fasting blood samples were collected at baseline and at the end of each intervention period. Compliance was excellent as indicated by capsule count and changes in resveratrol and dihydroresveratrol concentrations. No difference between resveratrol and placebo was found in any of the fasting serum or plasma metabolic risk markers (mean ± SD for differences between day 28 values of resveratrol vs. placebo: apoA-I; 0.00 ± 0.12 g/L (P = 0.791), apoB100; -0.01 ± 0.11 g/L (P = 0.545), HDL cholesterol; 0.00 ± 0.09 mmol/L (P = 0.721), LDL cholesterol -0.03 ± 0.57 mmol/L (P = 0.718), triacylglycerol; 0.10 ± 0.54 mmol/L (P = 0.687), glucose; -0.08 ± 0.28 mmol/L (P = 0.064), insulin; -0.3 ± 2.5 mU/L (P = 0.516)). Also, no effects on plasma markers for inflammation and endothelial function were observed. No adverse events related to resveratrol intake were observed. 150 mg of daily resveratrol intake for 4 weeks does not change metabolic risk markers related to cardiovascular health in overweight and slightly obese men and women. Effects on glucose metabolism warrant further study. NCT01364961.
    PLoS ONE 01/2015; 10(3):e0118393. DOI:10.1371/journal.pone.0118393 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Respiratory chambers are the current gold standard for assessing human energy expenditure and substrate utilization over a long period of time (several hours to several days), based on oxygen consumption, carbon dioxide production, and urinary nitrogen excretion. Analysis of human energy metabolism using a respiratory chamber provides information about the total energy expenditure (TEE), sleeping metabolic rate (SMR), resting metabolic rate, diet-induced thermogenesis (DIT), activity-induced thermogenesis (AIT), and substrate oxidation. In this review, we describe the theoretical underpinnings of the respiratory chamber, as well as the measurement reproducibility and applications as study endpoints for indirect calorimetry. In humans, the coefficients of variation in energy expenditure and substrate utilization were estimated by 24-h repeatability studies. Under the appropriate conditions, the coefficients of variation for TEE were 1% to 5%, SMR was around 1%, DIT was around 40%, AIT was around 10%, and substrate oxidation was around 5%. Factors that impact energy expenditure and sub-strate oxidation have been reported, and future weight changes can be predicted based on the 24-h respiratory quotient and substrate oxidation. As the 24-h energy expenditure and substrate oxidation are affected by the 24-h energy balance, it is important to consider the subject's energy balance prior to and during calorimetry. Accurate measurements of energy and substrate balance (intake minus utilization) will contribute to a better understanding of the conditions that lead to changes in body weight. Properly obtaining measurements using a respiratory chamber requires a thorough understanding of the measurement principles and calculation methods, as well as an appropriate protocol. Keywords : indirect calorimetry, coefficient of variance, energy balance, energy expenditure components , substrate oxidation
    01/2013; 2(1):93-99. DOI:10.7600/jpfsm.2.93
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, and toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combatting diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.
    Ageing research reviews 01/2015; 21. DOI:10.1016/j.arr.2015.01.002 · 7.63 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014